Evidence map›Paper›PMID 38833260›Full record

Observational studyInvestigative ophthalmology & visual science2024

Self-Reported Functional Vision in USH2A-Associated Retinal Degeneration as Measured by the Michigan Retinal Degeneration Questionnaire.

Bela Parekh, Jacque L Duncan, Lassana Samarakoon, Michele Melia, Maria Fernanda Abalem, Chris A Andrews, Isabelle Audo, Allison R Ayala, Chris Bradley, Janet K Cheetham and 13 more

Abstract readObservational Study
In one paragraph

Observational study in Investigative ophthalmology & visual science, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Bela ParekhDepartment of Ophthalmology and Visual Sciences, Kellogg Eye Center, University of Michigan, Ann Arbor, Michigan, United States.
Jacque L DuncanUniversity of California, San Francisco, San Francisco, California, United States.
Lassana SamarakoonJaeb Center for Health Research, Tampa, Florida, United States.
Michele MeliaJaeb Center for Health Research, Tampa, Florida, United States.
Maria Fernanda AbalemDepartment of Ophthalmology and Visual Sciences, Kellogg Eye Center, University of Michigan, Ann Arbor, Michigan, United States.
Chris A AndrewsDepartment of Ophthalmology and Visual Sciences, Kellogg Eye Center, University of Michigan, Ann Arbor, Michigan, United States.
Isabelle AudoInstitut de la Vision, Sorbonne Université, INSERM, CNRS, Paris, France.
Allison R AyalaJaeb Center for Health Research, Tampa, Florida, United States.
Chris BradleyWilmer Eye Institute, Johns Hopkins University, Baltimore, Maryland, United States.
Janet K CheethamFoundation Fighting Blindness, Columbia, Maryland, United States.
Gislin DagnelieWilmer Eye Institute, Johns Hopkins University, Baltimore, Maryland, United States.
Todd A DurhamFoundation Fighting Blindness, Columbia, Maryland, United States.
Rachel M HuckfeldtMassachusetts Eye and Ear Institute, Boston, Massachusetts, United States.
Gabrielle D LacyDepartment of Ophthalmology and Visual Sciences, Kellogg Eye Center, University of Michigan, Ann Arbor, Michigan, United States.
Brett MalbinDepartment of Ophthalmology and Visual Sciences, Kellogg Eye Center, University of Michigan, Ann Arbor, Michigan, United States.
Michel MichaelidesMoorfields Eye Hospital and UCL Institute of Ophthalmology, London, United Kingdom.
David C MuschDepartment of Ophthalmology and Visual Sciences, Kellogg Eye Center, University of Michigan, Ann Arbor, Michigan, United States.
Nicholas Peck-DimitDepartment of Ophthalmology and Visual Sciences, Kellogg Eye Center, University of Michigan, Ann Arbor, Michigan, United States.
Katarina StinglUniversity Eye Hospital, Center for Ophthalmology, University of Tübingen, Tübingen, Germany.
Christina Y WengBaylor College of Medicine, Houston, Texas, United States.
Alex Z ZmejkoskiDepartment of Ophthalmology and Visual Sciences, Kellogg Eye Center, University of Michigan, Ann Arbor, Michigan, United States.
K Thiran JayasunderaDepartment of Ophthalmology and Visual Sciences, Kellogg Eye Center, University of Michigan, Ann Arbor, Michigan, United States.
Foundation Fighting Blindness Clinical Consortium Investigator Group

Funding

Rapid-Prototyping and Design CoreP30EY002162 · NEI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ULLIAN, ERIK M · 1985 to 2024
$16.8M
Foundation Fighting Blindness RUSH2A - CONSORTIUM - 2016NEI NIH HHS P30 EY002162
6 · The paper itself

Abstract

Purpose: The purpose of this study was to evaluate self-reported functional vision (FV) and the impact of vision loss in patients with USH2A-associated retinal degeneration using a patient-reported outcome (PRO) measure, the Michigan Retinal Degeneration Questionnaire (MRDQ), to correlate MRDQ scores with well-established visual function measurements. Design: An observational cross-sectional study (n = 93) of participants who had Usher Syndrome Type 2 (USH2, n = 55) or autosomal recessive non-syndromic retinitis pigmentosa (ARRP; n = 38) associated with biallelic variants in the USH2A gene. Methods: The study protocol was approved by all ethics boards and informed consent was obtained from each participant. Participants completed the MRDQ at the 48-month study follow-up visit. Disease duration was self-reported by participants. One-way ANOVA was used to compare subgroups (clinical diagnosis, age, disease duration, and full-field stimulus threshold [FST] Blue-Red mediation) on mean scores per domain. Spearman correlation coefficients were used to assess associations between MRDQ domains and visual/retinal function assessments. Results: Of the study sample, 58% were female participants and the median disease duration was 13 years. MRDQ domains were sensitive to differences between subgroups of clinical diagnosis, age, disease duration, and FST Blue-Red mediation. MRDQ domains correlated with static perimetry, microperimetry, full-field stimulus testing, and best-corrected visual acuity (BCVA). Conclusions: Self-reported FV measured by the MRDQ, when applied to USH2 and ARRP participants, had good distributional characteristics and correlated well with visual function tests. MRDQ adds a new dimension of understanding on vision-related functioning and establishes this PRO tool as an informative measure in evaluating USH2A outcomes.

Indexed as

Extracellular Matrix ProteinsSelf ReportUsher SyndromesVisual AcuityAdolescentAdultAgedCross-Sectional StudiesFemaleHumansMaleMiddle AgedQuality of LifeRetinal DegenerationRetinitis PigmentosaSurveys and QuestionnairesExtracellular Matrix ProteinsUSH2A protein, human

Identifiers

PMID38833260
PMCPMC11156206

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.